OR | 95% CI | P value | |
Fatty liver | 1.36 | 1.30 to 1.42 | <0.001 |
Age categories | |||
18–44 | Reference | ||
45–64 | 1.82 | 1.74 to 1.89 | <0.001 |
>65 | 1.69 | 1.60 to 1.77 | <0.001 |
Sex | |||
Male | Reference | ||
Female | 1.13 | 1.11 to 1.6 | <0.001 |
Race | |||
Caucasian | Reference | ||
African American | 0.86 | 0.83 to 0.89 | <0.001 |
Hispanic | 0.84 | 0.81 to 0.88 | <0.001 |
Asian/Pacific Islander | 0.76 | 0.71 to 0.81 | <0.001 |
Native American | 1.21 | 1.06 to 1.37 | <0.001 |
Other | 0.87 | 0.81 to 0.93 | <0.001 |
Median household income | |||
Lowest quartile | Reference | ||
Second quartile | 0.86 | 0.83 to 0.90 | <0.001 |
Third quartile | 0.79 | 0.76 to 0.82 | <0.001 |
Highest quartile | 0.77 | 0.72 to 0.82 | <0.001 |
Income quartiles | |||
Lowest quartile | Reference | ||
Second quartile | 1.05 | 1.01 to 1.08 | <0.001 |
Third quartile | 1.08 | 1.04 to 1.12 | <0.001 |
Highest quartile | 1.06 | 1.02 to 1.11 | <0.001 |
Comorbidities | |||
Gastro-oesophageal reflux disease | 1.13 | 1.11 to 1.16 | <0.001 |
Hyperlipidaemia | 0.81 | 0.79 to 0.83 | <0.001 |
Smoking | 0.84 | 0.82 to 0.86 | <0.001 |
Diabetes | 0.90 | 0.88 to 0.92 | <0.001 |
Hypertension | 1.06 | 1.03 to 1.09 | <0.001 |
Obesity | 0.75 | 0.73 to 0.77 | <0.001 |
Obstructive sleep apnoea | 0.84 | 0.81 to 0.87 | <0.001 |
Charlson Comorbidity Index | |||
0 | Reference | ||
1 | 1.47 | 1.42 to 1.53 | <0.001 |
2 | 1.87 | 1.79 to 1.95 | <0.001 |
3 or more | 2.40 | 2.30 to 2.50 | <0.001 |
Inflammatory bowel disease | 5.02 | 4.79 to 5.23 | <0.001 |
Significant values are in bold (p<0.05).
MAFLD, metabolic dysfunction-associated fatty liver disease.